TruAlt Bioenergy Releases Q4 FY26 Earnings Call Transcript
TruAlt Bioenergy's FY26 revenue was ₹1,704 crore, with EBITDA margin at 19.81%. The company commissioned five ethanol plants and is expanding into CBG and SAF. Two JVs, TruAlt Gas (with Sumitomo) and Leafiniti Bioenergy (with GAIL), are developing new CBG plants. An SAF plant is planned in Andhra Pradesh. The company also operates seven fuel retail outlets.
The announcement covers multiple aspects of the company's operations, including financial results, expansion plans in new verticals (CBG, SAF), and operational challenges in the core ethanol business. The diversification strategy and progress in new areas are significant, but the decline in revenue and profit from the ethanol segment warrants a medium impact assessment. Investors will be closely watching the implementation of new projects and the resolution of ethanol allocation issues.
The announcement provides a comprehensive update on the company's performance, strategic initiatives, and financial results. While there are positive developments in new business verticals like CBG and SAF, the financial performance shows a dip in revenue and profit compared to the previous year, mainly due to challenges in the ethanol sector's allocation policies. The company's outlook is cautiously optimistic, balanced by ongoing challenges and diversification efforts.
TruAlt Bioenergy Limited has released the transcript of its earnings conference call held on May 22, 2026. The call discussed the company's audited financial results for the quarter and year ended March 31, 2026. The transcript is also available on the company's website.
During the call, Managing Director Vijaykumar Nirani highlighted the company's transformation in FY25-26, including the commissioning of all five ethanol plants and the successful transition to dual-feed operations in three of them. This integration provides year-long operational flexibility and margin enhancement opportunities. He also discussed the government's roadmap for ethanol blending and recent policy changes impacting the sector.
The company faced challenges with ethanol allocation from Oil Marketing Companies (OMCs) for the ESY '25-'26 tender, receiving only 26 crore litres against a bid of 72 crore litres. Despite this, TruAlt has secured additional allocations from private OMCs and targets selling Extra Neutral Alcohol (ENA) to the potable alcohol industry, bringing their total potential sales to 41 crore litres. The company is also pursuing a court-mandated additional allocation of 15 crore litres.
In the Compressed Biogas (CBG) vertical, the first plant has shown significant improvement with an 85% plus capacity utilization, leading to a 100% revenue increase and over 55% EBITDA margin. TruAlt has formed two joint ventures, TruAlt Gas with Sumitomo Corporation and Leafiniti Bioenergy with GAIL, to expand its CBG capacity. Construction has commenced on three TruAlt Gas plants, expected to be commissioned by Q3 and Q4 of the current financial year. Leafiniti Bioenergy targets commissioning six CBG plants by Q4 of FY27, bringing the total CBG capacity to 162 tons per day.
For Sustainable Aviation Fuel (SAF), TruAlt has signed an MOU with the Government of Andhra Pradesh to set up a 10 crore litre per annum capacity SAF plant. The company has also signed a technology transfer agreement with Honeywell UOP and is in advanced stages of securing offtake contracts.
In the fuel retail segment, TruAlt has commissioned seven retail outlets under a franchisee model and plans to add four more, bringing the total to 11. The company is considering expanding to over 90 outlets once crude prices stabilize.
Financially, the company reported a top-line of ₹1,704 crores for FY26, down from ₹1,880 crores in FY25, attributed to lower ethanol tender allocations. However, EBITDA margin improved to 19.81% from 18.98%. Profit Before Tax (PBT) stood at ₹109.47 crores, down from ₹152.15 crores, primarily due to increased depreciation and finance costs from plant capitalization. Profit After Tax (PAT) was ₹80.26 crores compared to ₹140 crores in the previous year. Consolidated financials showed a top-line of ₹1,813 crores and PAT of ₹96.86 crores for FY26.
The company is actively diversifying its revenue streams across ethanol, CBG, SAF, and fuel retail to reduce dependence on single revenue sources and government policies.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.